Sign in

You're signed outSign in or to get full access.

Karen Batungbacal

Director at IBEX
Board

About Karen Batungbacal

Karen Batungbacal, age 64, has served as an independent director of IBEX since January 20, 2025; she chairs the Compensation Committee. She holds an M.A. in Chemical Engineering from Princeton University and a B.S. in Chemical Engineering from the University of Notre Dame. Her selection emphasized executive leadership in shared services/BPO, and deep industry experience across financial services and healthcare.

Past Roles

OrganizationRoleTenureCommittees/Impact
Tenet HealthcareCountry Head, Global Business CenterNov 2019–Oct 2020Led GBS operations (healthcare domain)
UnitedHealth Group (Optum Global Services)SVPMar 2018–Aug 2019Global shared services leadership (healthcare)
QBE InsuranceExecutive General ManagerOct 2013–Oct 2017Financial services operations leadership
JPMorgan Chase & Co.Managing DirectorAug 2010–Jul 2012Offshoring/outsourcing leadership experience
ICT Group PhilippinesPresident2004–2010BPO operations leadership
Source One AsiaChief Executive Officer2002–2004BPO/outsourcing operations

External Roles

OrganizationRoleTenureNotes
CEO Advisor Inc.PartnerSince Jun 2023Advisory leadership
Management Association of the PhilippinesSecretary and GovernorSince Jan 2023Governance in national business association
Call Center StudioBoard of AdvisorsCurrentBPO tech advisory
Virlanie Foundation, Inc.Board of TrusteesCurrentNon-profit governance
IT & Business Process Association of the Philippines, Inc.Board of TrusteesCurrentIndustry association oversight
Gallagher Insurance PhilippinesDirectorCurrentFinancial services board role
Fuse Financing Inc.DirectorCurrentFinancial services/fintech board role
Other public company boardsNoneNo current public company directorships

Board Governance

  • Independence: The Board determined Batungbacal is independent under Nasdaq standards; Audit Committee members also meet SEC/Nasdaq independence.
  • Committee assignments: Compensation Committee (Chair); Compensation Committee consists of Batungbacal and Mingzhe (JJ) Zhuang (both independent).
  • Board & committee activity: FY ended Jun 30, 2025—Board held 10 meetings; Audit 5; Compensation 2; Corporate Governance 1.
  • Attendance: Each director attended at least 75% of Board/committee meetings during the period served; seven directors attended the Dec 5, 2024 AGM.
  • Governance controls: Prohibitions on hedging and pledging of company securities for directors and employees (zero-cost collars, margin accounts, pledges, etc.).

Fixed Compensation

ComponentPolicy / AmountFY2025 ActualNotes
Annual cash retainer$75,000 (non-employee directors) $33,266 (pro-rata for time served) Paid monthly; travel reimbursement per policy
Committee chair feesAudit Chair +$15,000 (effective after AGM) N/A (Comp Chair; no disclosed chair fee uplift)Board approved following Compensation Committee recommendation

Performance Compensation

GrantGrant DateTypeShares/UnitsVestingPerformance MetricsGrant-date FV
New director awardFeb 14, 2025RSUs5,000 25% vest quarterly, commencing Apr 1, 2025 Service-based$136,500
FY2026 annual director program (approved)Post-AGM 2025RSUs + PSUsChairman: 4,500; Tenured: 4,166; New: pro-rata Plan-definedPSUs based on IBEX TSR vs peer companies (relative TSR) Not disclosed
PSU structure (company-wide grants)Nov 8, 2024PSUsTarget earned over three performance periods 1/3 eligible to vest each: Sep 30, 2025 (1-yr), Sep 30, 2026 (2-yr), Sep 30, 2027 (3-yr) Relative TSR vs peer indices/companies; up to 2x target earned; max value cap 5x grant-date FV Not disclosed

Plan-level protections and signals:

  • Non-employee director total annual compensation limit $450,000; first-year limit $900,000.
  • Change-in-control: Immediate vesting/exercisability at closing for certain awards; double-trigger acceleration if terminated without cause within two years following change-in-control for continued/assumed awards.
  • Clawback and whistleblower: A&R 2020 LTIP revises clawback provisions and adds whistleblower protections.
  • Repricing prohibition: Explicitly prohibits repricing/cash-out of underwater options/SARs without shareholder approval.
  • Dividend accrual restriction: No dividends/dividend equivalents paid unless and until awards vest; no dividends on options/SARs.

Other Directorships & Interlocks

CategoryCompaniesNotes
Current public boardsNoneNo disclosed public company interlocks
Private/non-profit boardsCall Center Studio; Gallagher Insurance Philippines; Fuse Financing Inc.; Virlanie Foundation; IBPAPNo disclosed related-party transactions involving Batungbacal; related-party items in proxy primarily involve TRGI arrangements.

Expertise & Qualifications

  • Technical/industry: Global operations in BPO/shared services; domain experience in healthcare and financial services; selection rationale emphasizes operational and industry expertise aligned to IBEX markets.
  • Education: Princeton M.A. (Chemical Engineering); Notre Dame B.S. (Chemical Engineering).

Equity Ownership

MeasureAmountAs-of DateNotes
Beneficial ownership (common shares)1,875Oct 3, 2025SEC beneficial ownership table
Outstanding RSUs4,375Jun 30, 2025Reflects unvested RSUs from Feb 14, 2025 grant
Hedging/pledgingProhibitedPolicyInsider Trading Policy prohibits hedging/pledging/margin accounts

Insider filings and transactions:

Filing/TransactionDateTypeSecurities TransactedPost-Transaction OwnershipSource
Initial ownershipJan 28, 2025Form 3
RSU award (director grant)Feb 14, 2025Form 4 (Award)5,0005,000

Governance Assessment

  • Strengths: Independent director; Compensation Committee chaired by Batungbacal with independent membership; use of independent compensation consultant (Exequity) and modernization of director equity program; robust LTIP provisions (double-trigger CIC, clawback, no repricing, dividend restrictions); strong anti-hedging/pledging policy.
  • Engagement: Board met 10 times in FY2025; directors met 75%+ attendance; AGM attendance evidenced.
  • Alignment: Introduction of annual RSU/PSU grants for directors linked to relative TSR improves pay-for-performance alignment; director compensation caps reduce inflation risk.
  • Potential conflicts/red flags: No director-specific related-party transactions disclosed involving Batungbacal; related-party items relate primarily to TRGI office sublease and benefits participation. No hedging/pledging permitted. No attendance or compensation anomalies disclosed for Batungbacal in FY2025.